China’s CanSino Enrolls More Than 20,000 in Late-Stage COVID-19 Vaccine Trial

CanSino Biologics has enrolled more than 20,000 participants in a global phase 3 study of its COVID-19 vaccine candidate, Ad5-nCoV, co-developed with a research arm of the Chinese military.

CanSino begun enrollment in September with plans to enroll up to 40,000 adults aged 18 and over, according to ClinicalTrials.gov. The trial is being conducted in Argentina, Pakistan, Russia, Mexico and Chile.

The adenovirus-based vaccine is one of five that China has progressed to phase 3 trials so far. The others include Sinovac’s CoronaVac, two candidates developed by the China National Biotec Group (Sinopharm) and one by Anhui Zhifei Longcom Biologic Pharmacy.